Gør som tusindvis af andre bogelskere
Tilmeld dig nyhedsbrevet og få gode tilbud og inspiration til din næste læsning.
Ved tilmelding accepterer du vores persondatapolitik.Du kan altid afmelde dig igen.
This book on migraine is the first machine-generated scientific book in medicine published by Springer Nature, and reflects a new publication format which focuses on literature reviews: state-of-the-art computer algorithms were applied to select relevant sources from Springer Nature journal articles, rearrange them in a topical order, and provide short summaries of these articles. The result is the auto-summarization of current texts, organized by means of a similarity-based clustering routine in coherent chapters and sections. The human intervention of a world-renowned expert in this field grants the scientific soundness and appropriate organization of the contents identified. The AI-based approach seemed especially suitable to provide an innovative perspective as the topics are indeed both complex, interdisciplinary and multidisciplinary, as is migraine, the most important among the chronic non communicable diseases under the age of 50s. The result of this innovative process will be of help especially for readers with limited time, interested in migraine and wishing to learn more about the subject quickly and particularly if they are new to the topic. Springer Nature seeks to support anyone who needs a fast and effective start in their content discovery journey: from the undergraduate student exploring interdisciplinary content, to Master or PhD-thesis developing research questions, to the practitioner seeking support materials, this book can serve as an inspiration, to name a few examples.
Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
Tilmeld dig nyhedsbrevet og få gode tilbud og inspiration til din næste læsning.
Ved tilmelding accepterer du vores persondatapolitik.